Summary The MIB-l antibody has been raised against recombinant parts of the Ki-67 antigen and, unlike Ki-67, has wider application to routinely fixed specimens. The aim of this study was to compare the usefulness of MIB-l with S-phase fraction (SPF) as a measure of proliferation. A total of 75 patients with operable breast cancer were studied, 44 (median age 56 years) before any treatment and 31 (median age 68 years) after primary medical hormonal therapy. Sections from formalin-fixed paraffin-embedded tissue were stained with the MIB-1 antibody and a percentage score of positively stained cells obtained. SPF was measured by flow cytometry in fine-needle aspiration samples taken from the same lesion in each patient. Median MIB-1 score was 9% and median SPF was 1. 1%. A close correlation was found between MIB-1 score and SPF (rho = 0.59, P < 0.0001). There was a difference in the strength of the correlation found between the no treatment group and the treatment group, however, 95% confidence intervals for the rho values overlapped, indicating that there was no significant statistical difference. When analysed for ploidy status a correlation was found only in aneuploid tumours. MIB-l immunostaining can be used as an effective method of assessing proliferation in human breast carcinomas. This can be done using simple, widely available technology and provides the opportunity to perform large-scale retrospective analyses of archival material.
The assessment of the proliferative activity of breast carcinomas has been shown to be of prognostic significance using a number of different methodologies. Several long-term follow-up studies have demonstrated proliferative indices to be predictive for relapse-free and overall survival using both thymidine labelling index (TLI) (Tubiana et al., 1984; Silvestrini et al., 1985) and DNA flow cytometric determination of S-phase fraction (SPF) (Stal et al., 1993; Wenger et al., 1993; Camplejohn et al., 1994; Mansour et al., 1994) . SPF is considered by many to be the 'gold standard' for assessing tumour proliferation and is a widely used prognostic factor in some countries (Dressler et al., 1988; Wenger et al., 1993) .
The immunohistochemical determination of proliferation markers is an expanding area of research and use of the monoclonal antibody Ki-67 is now widely accepted. This antibody reacts with a nuclear antigen present in all cycling cells (Gerdes et al., 1984) . Ki-67 staining has been shown to be an independent prognostic factor with respect to early recurrence (Sahin et al., 1991; Wintzer et al., 1991; Veronese et al., 1993) , although follow-up renders conclusions about its relationship to survival premature. A number of studies have shown a significant correlation between Ki-67 staining and SPF in breast cancer (Walker and Camplejohn, 1988; Isola et al., 1990; Vielh et al., 1990; Gasparini et al., 1994) , however use of the Ki-67 antibody has methodological drawbacks, in particular the restriction of its use to frozen tissue.
MIB-1 is a recently developed monoclonal antibody that has been raised against recombinant parts of the Ki-67 antigen (Key et al., 1992) . It has been shown to correlate strongly with Ki-67 staining and has the advantage of reacting with epitopes in routinely fixed, wax-embedded specimens (Cattoretti et al., 1992) DNA flow cytometry Before surgical excision or core-cut biopsy, fine needle aspiration biopsies were taken from the same lesion using a 23 gauge needle. A cell suspension was made in 2 ml of minimal essential medium (Gibco) that was then snap frozen in liquid nitrogen.
For flow cytometric analysis the frozen cell suspension was thawed at 37°C, centrifuged at 1000 r.p.m. for 10 min and the pellet resuspended in 200 ul of PBS containing 0.5 mM EDTA, 0.5% Nonidet P-40 (Sigma), 20 ,ug ml-' propidium iodide, 200 jig ml-1 RNAase (Sigma), pH 7.2 (Larsen, 1994 (Zar, 1984) . Comparisons between DNA aneuploid tumours and diploid tumours for MIB-1 were made using the Mann-Whitney Utest.
Results
MIB-1 staining was confined to the cell nucleus, the majority of the sections were homogeneously stained and there was little background staining. While the intensity of staining varied from weak to very intense both within and between tumours, positive nuclei were readily identifiable (Figure 1) . The overall median MIB-1 score was 9.0% (range 1-83.4%). The median MIB-1 score in the no treatment group was 8.6% (range 1.9-83.4%) and 9.6% (range 1-64.9%) in the treatment group. The mean coefficient of variation for the flow cytometry analyses was 7.2 + 0.2 (s.e.m.). Of 75 tumours, 29 were diploid and 46 were aneuploid. The overall median SPF was 11.1% (range 0.5 -31.8%). The median SPFs in the treatment and no treatment groups were virtually identical: 11.0% (range 0.5-31.8%) and 11.1% (range 1.6-30.6%) respectively.
Using Spearman's rank correlation analysis there was a close relationship between MIB-1 score and SPF (rho=0.59, 95% CI 0.48 -0.76, P < 0.0001, Figure 2 ). The strength of this correlation appeared to differ between the no treatment group (rho=0.54, 95% CI 0.33-0.75, P<0.0001) and the treatment group (rho=0.71, 95% CI 0.51-0.87, P<0.0001). However, the overlapping 95% confidence intervals for the rho values indicated that this difference was not significant.
The median MIB-1 score was significantly higher in the DNA aneuploid tumours (11.6% n=46) than in the diploid tumours (5.5%, n=29) (Mann-Whitney U-test P<0.004, Figure 3 ). When the relationship between MIB-1 and SPF was analysed according to ploidy status the previously noted correlation was detected only in the aneuploid tumours (rho = 0.71, P <0.0001). No significant correlation was detected in diploid tumours (rho = 0.26, P = 0.16) (Figure 4 ).
Discussion
The measurement of tumour proliferation is becoming increasingly important in the field of breast cancer research. Not only has proliferative activity been shown to be a prognostic indicator (Tubiana et al., 1984; Silvestrini et al., 1985; Stal et al., 1993; Wenger et al., 1993; Camplejohn et al., 1994; Mansour et al., 1994) Comparison of MIB-1 with SPF revealed a good correlation between the two methods. In addition, this correlation was maintained in those patients treated with various endocrine agents. When analysed in relation to ploidy status the correlation was only seen in the aneuploid tumours, a finding also seen in studies comparing (Isola et al., 1990; Vielh et al., 1990) . The fact that MIB-1 scores were higher in aneuploid tumours in this study is also in keeping with other studies suggesting similar results for proliferation using SPF or (Isola et al., 1990; Camplejohn et al., 1994) .
There have been no previous studies comparing MIB-1 and SPF in breast cancer, however, Pinder et al. (1995) have recently published a study measuring MIB-1 in 177 patients, demonstrating a significant association with histological grade and confirming tumour growth fraction using this marker as an important predictor of survival. MIB-1 has been shown to be correlated with established measures of proliferation in other tumour types. Onda et al. (1994) found a very close correlation between MIB-1 and bromodeoxyuridine labelling index in 90 cases of cerebral glioma (r=0.96), while a study of 41 patients with malignant lymphoma showed a correlation between MIB-l and SPF (r = 0.51) (Pich et al., 1994) . A number of authors have looked at the relationship between SPF and Ki-67 in human breast tumours. Isola et al. (1990) found that Ki-67 correlated with SPF in a study of 102 cases (r=0.51), while two other studies of 96 cases (r = 0.30) (Vielh et al., 1990) , and 168 cases (rho =0.38) (Gasparini et al., 1994) also found significant correlations between these two methods. Given the fact that MIB-1 is raised against recombinant parts of the Ki-67 antigen, a similar result would be expected for the correlation of both these methods and SPF. Our results confirm this and, along with the studies presented in other tumour types (Onda et al., 1994; Pich et al., 1994) , raise the suggestion that there may be a slightly stronger correlation between MIB-1 and SPF, compared with Ki-67 and SPF. A possible explanation for this may be that antigenic preservation of Ki-67 protein is better in formalin-fixed paraffin sections than in frozen sections (Shi et al., 1991) .
Although overall there was a correlation between MIB-1 and SPF, as with reported studies looking at Ki-67 and SPF (Isola et al., 1990; Vielh et al., 1990) several different groups of tumours were apparent. In the majority of cases there was a close correlation between the two variables but with a higher MIB-1 score compared with SPF. This is to be expected and is explained by the fact that MIB-1 binds to a nuclear antigen expressed during the GI, G2 and M phases of the cell cycle, as well as in S-phase. In a significant proportion of tumours, however, MIB-1 score was lower than SPF, particularly those where MIB-1 was very low. It has been shown that some tumour cells arrested in S-phase are not recognised by the Ki-67 antibody (Van Dierendonck et al., 1989; Vielh et al., 1990) and it is likely that this may also apply to MIB-1. It is also possible that any error in calculating the percentage of cells in S-phase may be accentuated in tumours with very low proliferative activity, leading to an overestimation of S-phase. This may explain the apparent anomaly in our series of the median MIB-1 value being slightly lower than the median S-phase value. Other sampling errors may also lead to differences between these two techniques. Tumour (Remvikos et al., 1988; Fernando et al., 1994) , and it has been suggested that the yield of samples in which SPF can be estimated may in fact be increased by using FNAB (Remvikos et al., 1989) .
DNA flow cytometric estimation of SPF remains an important technique, however not all laboratories have access to such high-technology equipment. In addition, SPF can only be estimated in a proportion of tumours (approximately 75-85%) (Camplejohn et al., 1994) for a number of reasons, including low cellularity of the sample, obstructing cell debris, and overlapping aneuploid peaks. Immunohistochemical analysis with Ki-67 or MIB-1 allows estimation of proliferation index in virtually 100% of specimens. Unlike flow cytometry, it also offers simultaneous evaluation of tumour histology. The principal drawback of the antibody is that the antigen does not survive routine histological fixation and its application is restricted to fresh tissue. MIB-1 immunostaining, however, combines strong immunoreactivity with optimal preservation of morphology and can be easily applied to routinely fixed and waxembedded specimens.
In summary, we have shown that MIB-1 reactivity correlates with SPF, an established proliferation assay. It is a technique that can accurately measure cell proliferation in breast carcinomas using simple, widely available technology that is neither time-consuming, expensive, nor labour intensive. Its use thus provides the opportunity to perform large-scale retrospective analyses of archival material.
